Research Analysts Set Expectations for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will earn ($0.88) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period last year, the company earned ($0.73) earnings per share.

XENE has been the topic of a number of other research reports. Raymond James restated an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Wedbush lowered their target price on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Finally, William Blair upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $57.45.

Xenon Pharmaceuticals Price Performance

XENE stock opened at $39.83 on Friday. The company has a 50 day moving average price of $41.21 and a 200 day moving average price of $40.34. Xenon Pharmaceuticals has a fifty-two week low of $28.10 and a fifty-two week high of $50.99. The stock has a market capitalization of $3.04 billion, a PE ratio of -14.12 and a beta of 1.25.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in XENE. Janus Henderson Group PLC raised its position in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after purchasing an additional 1,507,135 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Xenon Pharmaceuticals by 82.0% during the first quarter. Affinity Asset Advisors LLC now owns 837,387 shares of the biopharmaceutical company’s stock valued at $36,050,000 after acquiring an additional 377,387 shares in the last quarter. Logos Global Management LP bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth $14,621,000. Vestal Point Capital LP increased its stake in Xenon Pharmaceuticals by 57.1% during the 3rd quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock valued at $32,480,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Ikarian Capital LLC raised its holdings in Xenon Pharmaceuticals by 169.6% during the first quarter. Ikarian Capital LLC now owns 107,187 shares of the biopharmaceutical company’s stock worth $4,614,000 after buying an additional 261,276 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.